RxDoctor Payments Data

Temitope Soares, MD

Dermatology · Spring, TXNPI 1619950383

Payments from drug & device makers

$19,645in general payments, 2019–2025

Across 926 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • Johnson & Johnson$2K
  • AbbVie$2K
  • Novartis$2K
  • Lilly USA, LLC$1K
  • Arcutis Biotherapeutics, Inc.$951
  • plus $9K from 28 others

What the payments were for

  • Consulting fees$1,6508%
  • Food & beverage$17,49489%
  • Education$5013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,645 in reported general payments places this provider in the 80th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$152,465
Medicare patients
390
Services billed
1,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab21$147,824
Dupixent SyringeDupilumab38$141,791
OtezlaApremilast12$55,980
JubliaEfinaconazole17$12,010
Tovet EmollientClobetasol Propionate/Emoll25$10,270
Clobetasol Propionate252$9,982
Fluocinonide77$2,702
Doxepin Hcl118$1,972
Mupirocin200$1,868
Metronidazole16$1,863
Doxycycline Hyclate65$1,166
Hydrocortisone47$621
Cephalexin113$561
Ketoconazole43$551
Triamcinolone Acetonide71$540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$521$55,98012 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$882$12,01017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Spring

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →